Table 1.
Patient demographics, Antiretroviral Therapy History and Clinical Data
| Characteristic: | HIV-negative | HIV-positive, ART-naïve | HIV-positive ART medicated >12 mo | p value |
|---|---|---|---|---|
| Number of Subjects | 20 | 20 | 20 | - |
| Age at death, mean ± SD | 42.8 ± 5.6 | 39.7 ± 7.3 | 45.3 ± 6.7 | 0.032a |
| Hours post-mortem, mean ± SD | 9.9 ± 5.7 | 10.0 ± 6.4 | 12.4 ± 7.9 | 0.455a |
| Sex | ||||
| Male (%) | 80% | 90% | 80% | 0.619b |
| Female (%) | 20% | 10% | 20% | |
| Race | ||||
| White (%) | 11 (55%) | 12 (60%) | 15 (75%) | 0.498b |
| Black (%) | 7 (35%) | 8 (40%) | 5 (25%) | |
| Other/Unknown (%) | 2 (10%) | 0 (0%) | 1 (5%) | |
| Ethnicity | ||||
| Hispanic (%) | 5 (25%) | 3 (15%) | 3 (15%) | 0.641b |
| Non-Hispanic (%) | 15 (75%) | 17 (85%) | 17 (85%) | |
| Neurocognitive Impairment Status | ||||
| HAND (%) | - | 6 (30%) | 14 (70%) | 0.009b |
| Neuropsych. Impair. Other Origin (%) | - | 5 (25%) | 4 (20%) | |
| Neurocognitively Normal (%) | - | 1 (5%) | 2 (10%) | |
| No Neurocognitive Data (%) | - | 8 (40%) | 0 (0%) | |
| ARV Treatment Status | ||||
| PI-Experienced (%) | - | - | 17 (85%) | |
| PI-Naïve (%) | - | - | 3 (15%) | |
| NRTI-Experienced (%) | - | - | 20 (100%) | |
| NRTI-Naïve (%) | - | - | 0 (0%) | |
| Disease Parameters | ||||
| HIVE (%) | - | 6 (30%) | 1 (5%) | |
| Log Plasma HIV c/mL, mean ± SD | - | 4.1 ± 1.4 | 4.7 ± 1.1 | 0.196c |
| Log Brain HIV g/mL, mean ± SD | - | 3.4 ± 1.9 | 4.1 ± 0.9 | 0.358c |
| Log CSF HIV c/mL, mean ± SD | - | 3.4 ± 1.8 | 2.8 ± 1.1 | 0.261c |
| CD4+ lymphocytes/mm3, mean ± SD | - | 108 ± 118 | 85 ± 118 | 0.624c |
ART, antiretroviral Therapy; ARV, antiretroviral; HAND, HIV-Associated Neurocognitive Disorders; Neuropsych. Impair., neuropsychiatric impairment; PI, HIV protease inhibitor; NRTI, nucleoside reverse transcriptase inhibitor, HIVE, HIV encephalitis; mo, months.
a
Analysis of Variance (ANOVA) p value.
b
Chi-square test p value.
c
Student t-test p value.